Individual #00404843

ID_report ?
Reference PubMed: Wang 2016
Remarks -
Gender M
Consanguinity -
Country -
Population white
Age at death -
VIP -
Data_av -
Treatment intravitreous injection of 0.5 mg ranibizumab in the right eye
Panel size 1
Diseases retinal disease
Owner name LOVD
Database submission license Creative Commons Attribution 4.0 InternationalCreative Commons License
Created by Anna Tracewska
Date created 2022-03-09 14:17:37 +01:00 (CET)
Date last edited N/A


Phenotypes

retinal disease (-)   Add phenotype for this disease

AscendingPhenotype ID     

Phenotype details     

Diagnosis/Initial     

Diagnosis/Definite     

Inheritance     

Age/Examination     

Age/Diagnosis     

Age/Onset     

Phenotype/Onset     

Protein     

Owner     
0000297407 33y: best-corrected visual acuity (BCVA) right/left eye: 20/100 / 20/250 in the left eye; ophthalmoscopy: right eye showed a sharply circumscribed vitelliform lesion in the center of the macula characteristic of pattern dystrophy primarily involving the retinal pigment epithelium, left eye showed a scar from choroidal neovascularization (CNV) that had developed 5 years before this initial decline in vision in the right eye; fluorescein angiography (FA) of the right eye in the early phase frames: hyperfluorescence corresponding to the extent of the vitelliform material with staining of this material but no definitive leakage in the late phase frames; visual acuity right eye gradually improved from 20/100 to 20/50 (5m) and 20/25 (9m later) with decreasing visualization of the vitelliform material on fundus photographs, FA: stable or slightly decreased staining of the material; optical coherence tomography: hyperreflective material in the subretinal space (2m) replaced by a hyporeflective area (5m and 9m of follow-up. 16m after reaccumulation of the visible vitelliform material, which became denser over the following 15 months. Optical coherence tomography: accumulation of the subretinal material of increased reflectivity on vertical cross sections; visual acuity remained stable at 20/25 until 31m after initial visit; 9 days after that urgent evaluation of an enlarged scotoma in the right eye for the last 2 days; visual acuity declined to 20/100 within the inferior margin of the lesion, fundus photography: less dense vitelliform material, FA: smaller area of hypofluorescence; FA: no fluorescein leakage from CNV on late phase frames; optical coherence tomography continued to show a large amount of the subretinal material of increased reflectivity; next 8 months, BCVA gradually improved to 20/25, correlating with decreasing amounts of the vitelliform material on red-free fundus photography and FA; optical coherence tomography: hyperreflective material in the subretinal space replaced by a hyporeflective area as the vitelliform material became less apparent on fundus photography. Next 18 months, visual acuity was stable, during which time the dense vitelliform material again appeared, disappeared, and reappeared within the inferior margin of the lesion on fundus photographs and late phase frames of FA; OCT changes reflected FA changes. 4m later (5y1m after initial visit) BCVA 20/125, FA: dense vitelliform material in the inferior half of the circular lesion; no leakage from CNV; OCT: large amount of the subretinal material of increased reflectivity, after 2m BCVA 20/63, 5m- 20/50, correlating with decreasing amounts of the vitelliform material in his right macula; 66-month follow-up visit: new subretinal hemorrhage was noted on a fundus photograph in the right eye; subretinal hemorrhage associated with CNV right eye,FA: distinctly abnormal vessels from CNV within the center of the macular lesion apparent in the early phase frame, corresponding with a hyperreflective area on the OCT. intravitreous injection of 0.5 mg ranibizumab in the right eye. 3m later stable BCVA, fundus photographs: resolution of subretinal hemorrhages, FA: staining of his CNV lesion in the early phase frames, with no new leakage in late phase frames to warrant - dystrophy, macular, vitelliform type 2 (VMD2) Familial, autosomal dominant 39y >20y - - anna_tracewska LOVD



Screenings


AscendingScreening ID     

Template     

Technique     

Tissue     

Remarks     

Genes screened     

Variants found     

Owner     
0000406083 DNA ? - - BEST1 1 LOVD



Variants

1 entry on 1 page. Showing entry 1.
Legend   How to query  

Chr     

Allele     

Effect     

Classification method     

Clinical classification     

AscendingDNA change (genomic) (hg19)     

DNA change (hg38)     

Published as     

ISCN     

DB-ID     

Variant remarks     

Reference     

ClinVar ID     

dbSNP ID     

Origin     

Segregation     

Frequency     

Re-site     

VIP     

Methylation     

Owner     

Gene     

IDbase Accession Number     

VariO/DNA     

VariO/Protein     

VariO/RNA     

Exon     

DNA change (cDNA)     

Haplotype     

RNA change     

Protein     

P-domain     

Exon_old     

Predicted     

Type/DNA     

Enzyme activity     

mRNA level     

Predict-BioInf     

Legacy protein change     

Protein level     
11 Unknown +?/. - likely pathogenic g.61724334A>G g.61956862A>G BEST1 p.Tyr167Cys:c.500A>G - BEST1_000364 heterozygous PubMed: Wang 2016 - - Unknown ? - - - - LOVD BEST1 - - - - - NM_004183.3:c.500A>G - r.(?) p.Tyr167Cys - - - - - - - - -
Legend   How to query  


Screenscraping/webscraping (downloading large amounts of data using scripts) is strictly prohibited.
Use our APIs to retrieve data.